The Claret European Growth Capital Fund III (‘the Fund’), a fund advised by Claret Capital Partners, backs Endomag, a medical technology company at the forefront of revolutionising breast cancer care.
Cambridge, July 24, 2023 – Endomag, a ground-breaking medical technology company at the forefront of revolutionising breast cancer care, have agreed a debt financing facility led by the Fund, to fuel Endomag’s mission to deliver innovative solutions for the detection and treatment of breast cancer.
Endomag’s technology is transforming the landscape of breast cancer treatment. By eliminating the need for radioactive materials in tumour and lymph node localisation, Endomag’s unique magnet-based technology offers a safer, more accessible alternative for breast cancer patients worldwide. This breakthrough innovation streamlines the surgical process and enhances patient outcomes.
“We are delighted to partner with Endomag as they continue to lead the way in cancer care innovation,” said David Bateman, Managing Partner at Claret Capital Partners. “Their revolutionary magnetic technology not only elevates the standard of care for breast cancer patients, but also presents a cost-effective and efficient solution for healthcare providers.”
This funding will support Endomag in further growing the business, bringing their breast cancer treatment products to even more patients. With the support of the Fund, Endomag is well-positioned to accelerate its remarkable growth trajectory and make a lasting impact in the field of cancer treatment worldwide.
“This backing from the Fund is not only an investment in Endomag, but also the thousands of surgeons and patients around the world using and benefiting from our technologies every day,” said Dr. Eric Mayes, CEO of Endomag. “These funds will further scale our mission to continue developing world-leading solutions that improve surgical outcomes, prevent unnecessary surgery when it’s not needed and increase patient access to vital cancer care.”